Impact of Intraoperative Intravenous Lidocaine Administered During Laparoscopic Colorectal Surgery on Remifentanil Consumption, Postoperative Pain and Immune Cell Activity: A Pilot Study

NCT03410836 Phase 4 UNKNOWN

This study evaluates the impact of intraoperative intravenous lidocaine administered during laparoscopic colorectal surgery on the intraoperative remifentanil consumption as well as postoperative pain and opioid requirements. It will evaluate immune cell activity for 48hours after surgical stress and general anesthesia with or without intravenous lidocaine.

Details

Lead sponsor	Ciusss de L'Est de l'Île de Montréal
Phase	Phase 4
Status	UNKNOWN
Enrolment	60
Start date	2019-04-29
Completion	2025-06

Conditions

• Intravenous Lidocaine and Immunity

Interventions

• intravenous lidocaine (IVL)
• Placebo

Primary outcomes

• Reduction of total intraoperative remifentanil consumption by 30% in the intravenous lidocaine ("IVL") group compared with the control group ("C"). Total consumption of remifentanil in mcg. — Intra-operative, 5 hours
  Reduction of total intraoperative remifentanil consumption by 30% in the intravenous lidocaine group compared with the control group.

Countries

Canada